Archives of Internal Medicine · 1981 · 45 citations · 0 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyPharmacodynamicsBlood Pressure ManagementHypertension ManagementHypertension PharmacotherapyIschemic Heart DiseaseWithdrawal SyndromesWithdrawing TreatmentAntihypertensive Drug TherapyAntihypertensive TreatmentPharmacologic Treatment Of WithdrawalPharmacological Management Of WithdrawalWithdrawal Discontinuation SyndromeWithdrawal Symptoms
• A review of the available literature concerning sudden withdrawal of antihypertensive drugs shows that withdrawal syndromes after cessation of such agents have occurred with β-blockers, methyldopa, clonidine hydrochloride, guanabenz, and bethanidine sulfate. Most commonly, these syndromes are limited to nervousness, tachycardia, headache, and nausea 36 to 72 hours after cessation of the drug. In rare cases, serious exacerbation of myocardial ischemia (β-blockers) or hypertension (clonidine, methyldopa) may occur in the posttreatment period. The withdrawal syndromes generally respond promptly to reinstitution of antihypertensive therapy. The infrequent occurrence of withdrawal syndromes should not discourage use of these efficacious agents. (<i>Arch Intern Med</i>1981;141:1125-1127)